PURPOSE: To evaluate the inhibitory effects of a urokinase-derived octapeptide A6 on laser-induced choroidal neovascularization (CNV). METHODS: In the first arm of the study, subcutaneous injection of A6 (200 mg/kg per day) into the right eyes in 20 rats and phosphate-buffered saline in 20 control rats was started 1 day before laser injury. Angiography was performed at week 2. To evaluate the dose response, a second arm of the study was performed in the left eyes. Half of the treatment group was treated with 400 mg/kg per day, and the remaining half continued to receive 200 mg/kg per day beginning on week 4. Laser injury was made at week 5 and angiography was performed at week 7. Angiographic evaluation, histopathologic evaluation including maximum CNV thickness and factor-VIII-stained endothelium counting were performed in the second arm of the study. Choroidal concentrations of A6 were measured. RESULTS: In the first arm of the study, angiography showed a 40.8% reduction in CNV in the 200-mg/kg per day treatment group, compared with the control (P = 0.0008). In the second arm of the study, angiographic reduction in CNV was 37.9% in the 200-mg/kg per day group (P = 0.0314) and 70.0% in the 400-mg/kg per day group (P = 0.0124), compared with the control. CNV was significantly less in the 400-mg/kg per day group than in the 200-mg/kg per day group (P = 0.0393). Both CNV thickness and number of endothelial cells were reduced in a dose-dependent manner and significantly less than in the control (P < 0.05). Mean choroidal concentration of A6 2 hours after injection was 0.72 micro M in the 200-mg/kg per day (100 mg/kg every 12 hours) and 1.75 micro M in the 400-mg/kg per day (200 mg/kg every 12 hours) treatment groups. Levels at 11 hours after injections were undetectable. CONCLUSIONS: A6 demonstrated antiangiogenic properties in a rat model of CNV and may be useful in the treatment of CNV.
PURPOSE: To evaluate the inhibitory effects of a urokinase-derived octapeptide A6 on laser-induced choroidal neovascularization (CNV). METHODS: In the first arm of the study, subcutaneous injection of A6 (200 mg/kg per day) into the right eyes in 20 rats and phosphate-buffered saline in 20 control rats was started 1 day before laser injury. Angiography was performed at week 2. To evaluate the dose response, a second arm of the study was performed in the left eyes. Half of the treatment group was treated with 400 mg/kg per day, and the remaining half continued to receive 200 mg/kg per day beginning on week 4. Laser injury was made at week 5 and angiography was performed at week 7. Angiographic evaluation, histopathologic evaluation including maximum CNV thickness and factor-VIII-stained endothelium counting were performed in the second arm of the study. Choroidal concentrations of A6 were measured. RESULTS: In the first arm of the study, angiography showed a 40.8% reduction in CNV in the 200-mg/kg per day treatment group, compared with the control (P = 0.0008). In the second arm of the study, angiographic reduction in CNV was 37.9% in the 200-mg/kg per day group (P = 0.0314) and 70.0% in the 400-mg/kg per day group (P = 0.0124), compared with the control. CNV was significantly less in the 400-mg/kg per day group than in the 200-mg/kg per day group (P = 0.0393). Both CNV thickness and number of endothelial cells were reduced in a dose-dependent manner and significantly less than in the control (P < 0.05). Mean choroidal concentration of A6 2 hours after injection was 0.72 micro M in the 200-mg/kg per day (100 mg/kg every 12 hours) and 1.75 micro M in the 400-mg/kg per day (200 mg/kg every 12 hours) treatment groups. Levels at 11 hours after injections were undetectable. CONCLUSIONS:A6 demonstrated antiangiogenic properties in a rat model of CNV and may be useful in the treatment of CNV.
Authors: T Takahashi; T Nakamura; A Hayashi; M Kamei; M Nakabayashi; A A Okada; N Tomita; Y Kaneda; Y Tano Journal: Am J Ophthalmol Date: 2000-12 Impact factor: 5.258
Authors: L Cheng; M E Rivero; C R Garcia; C D McDermott; K S Keefe; C A Wiley; K A Soules; G Bergeron-Lynn; S Vekich; K Zhang; K Appelt; W R Freeman Journal: J Ocul Pharmacol Ther Date: 2001-06 Impact factor: 2.671
Authors: Y Guo; A A Higazi; A Arakelian; B S Sachais; D Cines; R H Goldfarb; T R Jones; H Kwaan; A P Mazar; S A Rabbani Journal: FASEB J Date: 2000-07 Impact factor: 5.191
Authors: U Ozerdem; B Mach-Hofacre; L Cheng; S Chaidhawangul; K Keefe; C D McDermott; G Bergeron-Lynn; K Appelt; W R Freeman Journal: Curr Eye Res Date: 2000-06 Impact factor: 2.424
Authors: K Mishima; A P Mazar; A Gown; M Skelly; X D Ji; X D Wang; T R Jones; W K Cavenee; H J Huang Journal: Proc Natl Acad Sci U S A Date: 2000-07-18 Impact factor: 11.205
Authors: N Morlet; G G Graham; B Gatus; A J McLachlan; C Salonikas; D Naidoo; I Goldberg; C M Lam Journal: Antimicrob Agents Chemother Date: 2000-06 Impact factor: 5.191
Authors: Iryna A Falkenstein; Lingyun Cheng; Flossie Wong-Staal; Ajay M Tammewar; Erin C Barron; Gabriel A Silva; Qi-Xiang Li; Dehua Yu; Michelle Hysell; Guohong Liu; Ning Ke; James E Macdonald; William R Freeman Journal: Curr Eye Res Date: 2008-07 Impact factor: 2.424
Authors: Mei Chen; Jiangping Hou; Guilin Tan; Peng Xie; William R Freeman; James R Beadle; Karl Y Hostetler; Lingyun Cheng Journal: Drug Deliv Date: 2017-11 Impact factor: 6.419